Equity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is increasingly being shaped not by public institutions, but by ...

ORI Capital is planning a US$350 million fund to focus on Chinese biotech, with hopes that AI will help beat the market Hong Kong-based venture capital firm ORI Capital plans to launch a new fund to ...

Many people, including those with full-time jobs, often struggle to cover deductibles and copays for prescription drugs, even with insurance.  That is why Support Our Sheriffs Foundationtm and BI2 ...

A total of 2,53,370 students registered for pre-admission, submitting 8,11,643 applications across various undergraduate ...

The IPO pipeline in Hong Kong includes mainland Chinese A-share firms, US-listed Chinese firms and specialist companies ...

Report demonstrates that the N8 universities are not only major drivers of economic growth in the North of England – they are ...

Carlo Ratti's exhibition at the Venice Architecture Biennale 2025 is ambitious, very rich in ideas, projects, researches and ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

Please enter your username and password below, if you are not yet a member of BioTechniques remember you can register for ...

Shenzhen Zhongge Biotechnology Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding agent coupled to interleukin-1 receptor-associated ...

Unlike Trump’s first term, the pharmaceutical industry is in far more peril than it has ever been in, and the biotech industry needs to ask itself an important question: Where does it fit in ...

Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. "We successfully dosed the first patient in our ECLIPSE Phase 3 registrational program for hepatitis delta, a devastating disease with no ...